Key facts
- Cyrus Biotechnology’s last known valuation is $45.5M (Oct 2021).
- It has raised $36.6M across 10 recorded rounds; the latest was Seed Round ($1.5M) in Jul 2025.
- Notable investors include Alumni Ventures, US National Science Foundation, OrbiMed, Argonautic Ventures, iSelect Fund — 26 tracked in total.
- Cyrus Biotechnology has filed 13 Form Ds with the SEC since 2015, most recently May 2026 ($1.5M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 10 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Cyrus Biotechnology
Funding rounds
10 roundsAbout Cyrus Biotechnology
Operator of a biologic therapeutics company intended to treat serious diseases through advanced protein engineering. The company offers an internal immunogenicity redesign platform, combined with proprietary protein design and screening capabilities, enabling pharmaceutical and biotechnology sectors to develop safer and more effective treatments.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2014
- Employees
- 24
- Website
- cyrusbio.com/
- Ownership
- Privately Held (backing)
Cyrus Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cyrus Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cyrus Biotechnology in its N-PORT filings yet. We sweep new filings monthly.